Next Article in Journal
Macrophage Proteome Analysis at Different Stages of Mycobacterium avium Subspecies paratuberculosis Infection Reveals a Mechanism of Pathogen Dissemination
Next Article in Special Issue
Current State of SLC and ABC Transporters in the Skin and Their Relation to Sweat Metabolites and Skin Diseases
Previous Article in Journal
Small Mass but Strong Information: Diagnostic Ions Provide Crucial Clues to Correctly Identify Histone Lysine Modifications
Previous Article in Special Issue
Exosome-Derived Mediators as Potential Biomarkers for Cardiovascular Diseases: A Network Approach
 
 
Review
Peer-Review Record

Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance

by Giusj Monia Pugliese 1,†, Sara Latini 1,†, Giorgia Massacci 1, Livia Perfetto 2 and Francesca Sacco 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Submission received: 26 March 2021 / Revised: 22 April 2021 / Accepted: 24 April 2021 / Published: 27 April 2021
(This article belongs to the Special Issue Functional Proteomics 2020)

Round 1

Reviewer 1 Report

Minor

Figure 1: In the scheme of the ITD mutations of the JMD domain, put it in the same color as the tridimensional scheme, as with the TKD-1 domain.

Figure 1-line 161: Bold "landscape in the FLT3 gene."

Line 169: Lowercase "More".

The format of the references is not standardized, in some references the year of publication is not in bold, or even does not appear, as in the case of references 12, 31 or 53.

Author Response

Please see the attachment file

Author Response File: Author Response.docx

Reviewer 2 Report

Pugliese et al. submitted the manuscript "Combining Mass Spectrometry-based phosphoproteomics with 2 a network-based approach to reveal FLT3-dependent mecha-3 nisms of chemoresistance.". This is a very comprehensive and well written review. Comprehension of chemoresistance is very challenging and focus on only FLT3 mutated patients is a very interesting approach. 

Major comments:

  1. All TKI inhibitors have different kinome. Gilteritinib inhibits axl for example. How do you explain that what you described was only associated to FLT3 and not to the off target effects?
  2. Chemoresistance could be an intrinsec mechanism or a clonal evolution or selection: could you comment this point?
  3. Patients have usually co mutations, how do you exclude the impact of co mutations?

Author Response

Please see the attachment file

Author Response File: Author Response.docx

Reviewer 3 Report

This is a well-written review abounds with sufficient introduction of FLT3 and related proteomics platform. Minor thoughts:

  1. Single-cell proteomics is gaining more popularity whereas its technical challenges have not been well documented so far. Might as well loop in more information on this aspect.
  2. Phosphorylation of FLT3 can vary in different circumstances, from single site to multiple sites. May expand the details and relay them to the corresponding proteomics strategies.

Author Response

Please see the attachment file

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

The authors answered to all comments

Back to TopTop